Patent ID: 6268389
Filing Date: 2001-07-31
Classification: A61K,A61P,C07D

Abstract:
A method for the treatment of urinary incontinence which method comprises administering to a host suffering from urinary incontinence a therapeutically effective amount of an .alpha..sub.1L -adrenoceptor agonist which is a compound of the formulae lb ##STR17##wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are each, independently of one another:hydrogen, C.sub.1-6 -alkyl, C.sub.3-6 -cycloaklyl, C.sub.1-6 -alkoxy, halogen, --CF.sub.3, --OCF.sub.3, or --NR.sup.6 R.sup.7, wherein;R.sup.6 is hydrogen, C.sub.1-6 -alkyl, C.sub.3-6 -cycloalkyl or C.sub.2-4 -acyl;R.sup.7 is hydrogen, C.sub.1-6 -alkyl, C.sub.3-6 -cycloalkyl or C.sub.2-4 -acyl; or,R.sup.6 and R.sup.7 together with the nitrogen between them form a 5- or 6-membered, saturated or unsaturated ring which may contain up to two additional heteroatoms selected from oxygen, sulfur and nitrogen, wherein each additional heteroatom is unsubstituted or substituted by C.sub.1-4 -alkyl; orR.sup.6 and R.sup.7 together with the nitrogen between them form phthalimido; orR.sup.1 and R.sup.2 together form a fused pyrazole of the formula ##STR18##wherein R.sup.8 is C.sub.1-3 -alkyl, or a fused thiadiazole of the formula ##STR19##wherein R.sup.3, R.sup.4 and R.sup.5 are as hereinbefore defined in this claim, or a pharmaceutically acceptable salt thereof.